Full-Time

Associate Director – Clinical Pharmacology Lead

Posted on 5/9/2026

Deadline 5/15/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$124.4k - $207.4k/yr

No H1B Sponsorship

Cambridge, MA, USA + 2 more

More locations: Groton, CT, USA | New York, NY, USA

Hybrid

Hybrid role requiring on-site work averaging 2.5 days per week.

Category
Biology & Biotech (1)
Required Skills
R
Requirements
  • Pharm. D., M.D./Ph.D., or equivalent training/experience in pharmacokinetics, pharmacometrics, clinical pharmacology, engineering, or related discipline.
  • 1+ years of industry experience in clinical pharmacology and/or clinical PK/PD and/or Pharmacometrics/Systems Pharmacology.
  • Intimate knowledge of drug development and experience in applying quantitative pharmacology approaches to knowledge integration.
  • Strong quantitative skills and expertise (e.g. experience in mechanistic PK/PD modeling/systems pharmacology, literature meta-analyses, population modeling, and clinical trial simulations using NONMEM, R, etc.).
  • Excellent written and verbal communication skills.
  • Demonstrated presentation skills.
  • Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Responsibilities
  • Act as Clinical Pharmacology representative on Clinical Sub Team and Development Team and other multifunctional teams as appropriate.
  • Responsible for providing expertise, leadership, and deliverables of clinical pharmacology for the assigned projects within sphere of influence.
  • Design and execute clinical pharmacology plans and implement clinical pharmacology best practices on project teams.
  • Work closely with other disciplines to ensure that sufficient preclinical PK/PD knowledge exists to underwrite safe human administration and to establish the structure of a predictive model prior to FIH.
  • Responsible for planning and overseeing clinical pharmacology aspects at the project level (e.g clinical development plan, implementation and interpretation of PK/PD analyses, PK/immunogenicity/biomarker measurement strategies etc.).
  • Plan and oversee study level activities including protocol authoring, clinical phase oversight, and reporting.
  • Responsible (with clinicians and statisticians) for ensuring appropriate dose-range finding strategies which ultimately will lead to optimal doses and dosage regimens in patients.
  • Accountable for ensuring appropriate design and implementation of End-to-End MIDD plan that conforms with best practices.
  • Responsible for ensuring use of innovative analytical methods to integrate knowledge of PK, PD, patient characteristics and disease states to optimize doses, dosage regimens and study designs.
  • Provide End-to-End clinical pharmacology contribution to regulatory documents (e.g., Briefing documents, Regulatory queries, Investigator’s Brochures, IND, NDA/MAA, etc.).
  • Develop new methodologies through internal and/or external collaborations with world leading experts.
  • Coach less experienced colleagues and team members.
  • Stay abreast of literature, regulatory guidelines, and internal guidance and SOPs.
  • Influence external environment through publications, presentations, and representation at scientific societies and industrial consortium.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, offsetting COVID product declines.
  • VYNDAMAX patent extension to 2031 stabilizes 75% market share cardiology revenue.
  • ELREXFIO Phase 3 data positions multiple myeloma drug against J&J, BMS competitors.

What critics are saying

  • Eliquis patent expiration 2026-2027 eliminates $1.5B revenue via generic competition.
  • Ibrance patent cliff 2027 erodes $5B+ annual oncology revenue with no successor.
  • COVID product sales collapsed from $56.7B 2022 to $5B projected 2026.

What makes Pfizer unique

  • Seagen acquisition doubled oncology pipeline to 60 programs with proprietary ADC technology.
  • VEPPANU first FDA-approved oral PROTAC therapy for endocrine-resistant breast cancer.
  • HYMPAVZI EU approval targets 20% hemophilia A patients with inhibitors, 93% bleeding reduction.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.